Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
La radiologia medica
Published in: La radiologia medica 3/2019

01-03-2019 | ONCOLOGY IMAGING

Non-palliative radiotherapy in ab initio oligometastatic prostate cancer: an Italian national survey

Authors: Giorgia Timon, Barbara Alicja Jereczek-Fossa, Sergio Fersino, Cinzia Iotti, Renzo Corvò, Stefano Maria Magrini, Filippo Alongi

Published in: La radiologia medica | Issue 3/2019

Login to get access

Abstract

Aims

The purpose of this survey was to investigate the current opinion among Italian radiation oncologists regarding the non-palliative radiotherapy in ab initio oligometastatic prostate cancer (OMPC) patients.

Methods

A link to complete the survey was sent via e-mail to Italian radiation oncologists on February 2018. It was requested that only one physician per facility completed the survey, and that he/she was dedicated to PC management in his/her daily clinical practice. The questionnaire consisted of 15 questions concerning the management of OMPC.

Results

One hundred and eleven radiation oncologists filled in the questionnaire. The majority of them see ≤ 10 patients affected by OMPC in a year. More than 80% of respondents would perform radiotherapy (RT) to both the prostate and all metastases sites, but mostly up to 2–3 metastases; furthermore, > 80% of physicians would perform RT on both nodal and bone secondary lesions. Most respondents deem a choline- or prostate-specific membrane antigen (PSMA)-positron emission tomography (PET) mandatory before considering a patient affected by OMPC for non-palliative RT. The association of RT with androgen deprivation therapy for at least 12 months would be recommended by > 50% of respondents. In the follow-up phase, the majority would suggest a clinical examination and PSA every 3–6 months and a choline- or PSMA-PET only at biochemical progression. More than 90% of respondents confirmed to be interested in participating in a multicentre study regarding this subject.

Conclusions

This survey investigated the current opinion of Italian radiation oncologists and confirmed their interest in OMPC management.
Literature
1.
Vale CL, Fisher DJ, White IR et al (2018) What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis. Ann Oncol 29(5):1249–1257CrossRefPubMedPubMedCentral
2.
Gravis G, Gravis G, Boher JM et al (2018) Burden of metastatic castrate naive prostate cancer patients, to identify men more likely to benefit from early docetaxel: further analyses of CHAARTED and GETUG-AFU15 studies. Eur Urol 73(6):847–855CrossRefPubMedPubMedCentral
3.
Heidenreich A, Bastian PJ, Bellmunt J et al (2014) EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol 65:124–137CrossRef
4.
Arcangeli S, Zilli T, De Bari B, Alongi F (2016) “Hit the primary”: a paradigm shift in the treatment of metastatic prostate cancer? Crit Rev Oncol Hematol 97:231–237CrossRefPubMed
5.
6.
Gillessen S, Attard G, Beer TM et al (2018) Management of patients with advanced prostate cancer: the report of the advanced prostate cancer consensus conference APCCC 2017. Eur Urol 73(2):178–211CrossRef
7.
Francini E, Gray KP, Xie W et al (2018) Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC). Prostate 78(12):889–895CrossRefPubMedPubMedCentral
8.
Pillay B, Wootten AC, Crowe H et al (2016) The impact of multidisciplinary team meetings on patient assessment, management and outcomes in oncology settings: a systematic review of the literature. Cancer Treat Rev 42:56–72CrossRefPubMed
9.
Rao K, Manya K, Azad A et al (2014) Uro-oncology multidisciplinary meetings at an Australian tertiary referral centre—impact on clinical decision-making and implications for patient inclusion. BJU Int 114(Suppl 1):50–54CrossRefPubMed
10.
Kurpad R, Kim W, Rathmell WK et al (2011) A multidisciplinary approach to the management of urologic malignancies: does it influence diagnostic and treatment decisions? Urol Oncol 29(4):378–382CrossRefPubMed
11.
National Comprehensive Cancer Network clinical practice guidelines in oncology, version 3.2018. National Comprehensive Cancer Network 2011, Jenkintown. http://​www.​nccn.​org
12.
Pasoglou V, Larbi A, Collette L et al (2014) One-step TNM staging of high-risk prostate cancer using magnetic resonance imaging (MRI): toward an upfront simplified “all-in-one” imaging approach? Prostate 74(5):469–477CrossRefPubMed
13.
Larbi A, Dallaudière B, Pasoglou V et al (2016) Whole body MRI (WB-MRI) assessment of metastatic spread in prostate cancer: therapeutic perspectives on targeted management of oligometastatic disease. Prostate 76(11):1024–1033CrossRefPubMed
14.
Joice GA, Rowe SP, Pienta KJ, Gorin MA (2017) Oligometastatic prostate cancer: shaping the definition with molecular imaging and an improved understanding of tumor biology. Curr Opin Urol 27(6):533–541CrossRefPubMed
15.
16.
Ost P, Decaestecker K, Lambert B et al (2014) Prognostic factors influencing prostate cancer-specific survival in non-castrate patients with metastatic prostate cancer. Prostate 74:297–305CrossRefPubMed
17.
Saluja R, Cheung P, Zukotynski K, Emmenegger U (2016) Disease volume and distribution as drivers of treatment decisions in metastatic prostate cancer: from chemohormonal therapy to stereotactic ablative radiotherapy of oligometastases. Urol Oncol 34(5):225–232CrossRefPubMed
18.
De Bari B, Arcangeli S, Ciardo D, On the behalf of the Italian Association of Radiation Oncology (AIRO) et al (2016) Extreme hypofractionation for early prostate cancer: biology meets technology. Cancer Treat Rev 50:48–60CrossRefPubMed
19.
Nair R, Lamb BW, Geurts N et al (2017) The role of local therapy for oligometastatic prostate cancer: should we expect a cure? Urol Clin North Am 44(4):623–633CrossRefPubMed
20.
Cho Y, Chang JS, Rha KH et al (2016) Does radiotherapy for the primary tumor benefit prostate cancer patients with distant metastasis at initial diagnosis? PLoS ONE 11(1):e0147191CrossRefPubMedPubMedCentral
21.
Riva G, Marvaso G, Augugliaro M et al (2017) Cytoreductive prostate radiotherapy in oligometastatic prostate cancer: a single centre analysis of toxicity and clinical outcome. Ecancermedicalscience 30(11):786
22.
23.
Henderson DR, Tree AC, van As NJ (2015) Stereotactic body radiotherapy for prostate cancer. Clin Oncol (R Coll Radiol) 27(5):270–279CrossRef
24.
Miralbell R, Roberts SA, Zubizarreta E, Hendry JH (2012) Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: α/β = 1.4 (0.9–2.2) Gy. Int J Radiat Oncol Biol Phys 82(1):e17–e24CrossRefPubMed
25.
Evangelista L, Zattoni F, Guttilla A, Saladini G, Zattoni F, Colletti PM, Rubello D (2013) Choline PET or PET/CT and biochemical relapse of prostate cancer: a systematic review and meta-analysis. Clin Nucl Med 38(5):305–314CrossRefPubMed
Metadata
Title
Non-palliative radiotherapy in ab initio oligometastatic prostate cancer: an Italian national survey
Authors
Giorgia Timon
Barbara Alicja Jereczek-Fossa
Sergio Fersino
Cinzia Iotti
Renzo Corvò
Stefano Maria Magrini
Filippo Alongi
Publication date
01-03-2019
Publisher
Springer Milan
Published in
La radiologia medica / Issue 3/2019
Print ISSN: 0033-8362
Electronic ISSN: 1826-6983
DOI
https://doi.org/10.1007/s11547-018-0952-x

Other articles of this Issue 3/2019

La radiologia medica 3/2019 Go to the issue

ONCOLOGY IMAGING

Whole-body magnetic resonance imaging (WB-MRI) in oncology: recommendations and key uses

HEAD, NECK AND DENTAL RADIOLOGY

CT and MR imaging findings of infection-free and benign second branchial cleft cysts

ABDOMINAL RADIOLOGY

Contrast-enhanced ultrasound in the evaluation of splenic injury healing time and grade

ABDOMINAL RADIOLOGY

Contrast-enhanced ultrasound in delayed splenic vascular injury and active extravasation diagnosis

CARDIAC RADIOLOGY

Radiation dose and image quality with new protocol in lower extremity computed tomography angiography

RADIOTHERAPY

Evaluation of Italian radiotherapy research from 1985 to 2005: preliminary analysis